AtaiBeckley reports positive Phase 2b open-label extension results for intranasal 5-MeO-DMT in TRD and outlines Phase 3 expectations

5-MeO-DMT open-label extension data for AtaiBeckley in treatment-resistant depression suggests additional rapid antidepressant effects. After an 8-week blinded period using one of three intranasal first doses (0.3 mg, 8 mg, or 12 mg), participants were offered a second short-acting 12 mg dose during the open-label extension. The second dose produced additional clinically meaningful improvements that were sustained for up to eight weeks. The coverage frames these topline results as supporting progress toward a Phase 3 path, with AtaiBeckley positioning the follow-on dosing and durability of effects as key signals for further development.